Asian Journal of Pharmaceutical Sciences

Asian Journal of Pharmaceutical Sciences is the official journal of the Asian Federation for Pharmaceutical Sciences, hosted by Shenyang Pharmaceutical University and published by KeAi on the Elsevier platform, founded in 2006, covering all aspects of pharmaceutics, with a 2025 Journal Impact Factor of 12.6（Asian Journal of Pharmaceutical Sciences）（AJPS）是（Asian Federation for Pharmaceutical Sciences）的官方期刊，由（Shenyang Pharmaceutical University）主办并在（KeAi）（Elsevier）平台出版，2006 年创刊，涵盖药剂学各领域，2025 年影响因子为 12.6。

Scope

• It provides a forum for innovations, production methods, technologies and the application of scientific knowledge to all aspects of pharmaceutics为药剂学各领域的创新、生产方法、技术与科学知识应用提供交流平台。
• Its coverage includes controlled drug release systems and drug targeting报道范围涵盖控释给药系统与药物靶向。^[1]
• It covers physical pharmacy, pharmacodynamics and pharmacokinetics涵盖物理药剂学、药效学与药代动力学。
• It covers pharmacogenomics, biopharmaceutics and drug as well as prodrug design涵盖药物基因组学、生物药剂学以及药物与前药设计。^[2]
• It covers pharmaceutical analysis, drug stability and quality control涵盖药物分析、药物稳定性与质量控制。
• It also covers pharmaceutical engineering and material sciences还涵盖制药工程与材料科学。^[3]
• It publishes research articles, reviews, short communications, perspectives and comments刊载研究论文、综述、短通讯、观点与评论。

History

• It was founded in 2006 as the official journal of the Asian Federation for Pharmaceutical Sciences该刊于 2006 年创刊，是（Asian Federation for Pharmaceutical Sciences）的官方期刊。
• It was the first Chinese pharmaceutics journal indexed by the Science Citation Index Expanded该刊是中国首个被（Science Citation Index Expanded）收录的药剂学学术期刊。
• It is a bimonthly full-English journal and its China serial number is CN 21-1608/R该刊为全英文双月刊，国内统一连续出版物号为 CN 21-1608/R。
• It is a subsidized gold open access journal and Shenyang Pharmaceutical University pays the article publishing charge该刊为受资助的完全开放获取期刊，文章处理费由（Shenyang Pharmaceutical University）承担。
• It is indexed in Science Citation Index Expanded, Scopus and PubMed Central该刊被（Science Citation Index Expanded）、（Scopus）与（PubMed Central）收录。
• Its impact factor was 6.598 in 2021, 9.273 in 2022 and 12.6 in 2025其影响因子 2021 年为 6.598，2022 年为 9.273，2025 年为 12.6。
• Its articles are published on ScienceDirect under a CC BY-NC-ND license and a CC BY option may be requested文章在（ScienceDirect）平台以（CC BY-NC-ND）许可发布，作者亦可申请（CC BY）许可。

Editors

• The Editor-in-Chief is Zhonggui He of Shenyang Pharmaceutical University主编为（Shenyang Pharmaceutical University）的（Zhonggui He）。
• Hirofumi Takeuchi of Gifu Pharmaceutical University and Paul WS Heng of the National University of Singapore also serve as Editors-in-Chief（Gifu Pharmaceutical University）的（Hirofumi Takeuchi）与（National University of Singapore）的（Paul WS Heng）亦任主编。
• Associate Editors-in-Chief include Shirui Mao and Jin Sun of Shenyang Pharmaceutical University and Yu-Kyoung Oh of Seoul National University副主编包括（Shenyang Pharmaceutical University）的（Shirui Mao）与（Jin Sun）以及（Seoul National University）的（Yu-Kyoung Oh）。
• Honorary Editors-in-Chief are Tsuneji Nagai, Yoshiaki Kawashima and Fude Cui名誉主编为（Tsuneji Nagai）、（Yoshiaki Kawashima）与（Fude Cui）。
• Peer review is under the responsibility of Shenyang Pharmaceutical University and the board spans the Asia-Pacific region同行评审由（Shenyang Pharmaceutical University）负责，编委会覆盖亚太地区。
• Its editorial board members come from more than ten countries across Asia, Europe and North America其编委会成员来自亚洲、欧洲与北美十余个国家。